ZELSUVMI Drug Gets FDA Patent Extension Review Period
Published Date: 12/29/2025
Notice
Summary
The FDA has set the official review period for the drug ZELSUVMI, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting when generic versions can enter the market. People can comment or challenge these dates by early 2026, so stay tuned if you have info to share!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
FDA Sets ZELSUVMI Review Period
You may see a delay in generic competition because the FDA determined the regulatory review period for ZELSUVMI is 4,144 days in total — 3,778 days in the testing phase and 366 days in the approval phase. Those dates (IND effective September 2, 2012; NDA submitted January 5, 2023; approved January 5, 2024) form the basis for possible patent term restoration.
Company Seeks 1,280-Day Patent Extension
The patent applicant (LNHC, Inc.) is seeking 1,280 days of patent term extension for ZELSUVMI. Under law, a patent may be extended for up to 5 years, but the U.S. Patent and Trademark Office will apply statutory limits when calculating the actual extension.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in